Psilocybin and SSRIs: What You Need to Know Before Combining
About This Video
The SSRI-psilocybin interaction is the most clinically important drug interaction in the psychedelic space, given that 13% of Americans are on antidepressants and many are considering psilocybin therapy. This video from the Psychedelic Medicine Association covers the pharmacology clearly: chronic SSRI use downregulates 5-HT2A receptors, which are psilocybin's primary target, significantly blunting or eliminating the subjective and potentially therapeutic effects.
The video addresses the critical safety issue: people should never abruptly stop SSRIs to undergo a psilocybin session. Abrupt SSRI discontinuation causes discontinuation syndrome (brain zaps, dizziness, emotional instability) and can trigger rebound depression. The guidance is to discuss tapering with a prescribing physician — and to be honest about plans to use psilocybin, which is increasingly possible as more physicians become familiar with the research.
Key Takeaways
- SSRIs significantly blunt psilocybin effects by downregulating 5-HT2A receptors — many people on SSRIs report little to no effect from standard doses.
- Never abruptly stop SSRIs to use psilocybin — discontinuation syndrome is real and dangerous. Taper under medical supervision only.
- Some SNRIs and TCAs have similar blunting effects; MAOIs present a more serious interaction risk and should never be combined.
- Lithium combined with psychedelics has been associated with seizures — this is a hard contraindication.
- The clinical trial populations at Johns Hopkins and COMPASS excluded participants on SSRIs — blunting effects mean trial results may not apply to people currently medicated.
Dive Deeper
Continue exploring this topic on LearnShrooms: